Compare Novartis AG (NVS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Recursion Pharmaceuticals Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Novartis AG is far larger — about 189.7× Recursion Pharmaceuticals Inc's market cap, and Novartis AG pays a 3.17% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NVS | RXRX | |
|---|---|---|
Market Cap | $290.25B | $1.53B |
Sector | Health | Health |
52-Week High | $168.62 | $6.79 |
52-Week Low | $113.50 | $2.84 |
Enterprise Value | $330.27B | $946.50M |
Dividend Yield | 3.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
